Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155270 | 1.00 | SLC15A1 (0.53) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12873744 | 1.00 | SLC15A1 (0.53) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL20586458 | 0.99 | SLC15A1 (0.52) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL20586459 | 0.99 | SLC15A1 (0.52) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10974748 | 0.89 | SLC15A1 (0.47) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL15883746 | 0.89 | SLC15A1 (0.47) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL27131921 | 0.89 | SLC15A1 (0.47) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29871935 | 0.87 | SLC15A1 (0.46) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12155266 | 0.86 | LTA4H (0.61) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7740147 | 0.86 | LTA4H (0.61) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| CN-117136076-A | MCL-1 inhibitor antibody drug conjugates and methods of use | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-1042297-B1 | CARBOXYL ACID SUBSTITUTED HETEROCYCLES AS METALLOPROTEINASE INHIBITORS | AMGEN INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020065269-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. | 2002-05-30 | — | — | US | disclosed |
| US-6335329-B1 | N-SULFONYL-3-AMINOAZEPINE-2-CARBOXYLIC ACID DERIVATIVES; ANTIINFLAMMATORY, ANTICARCINOGENIC, AND ANTIARTHRITIC AGENTS; METALLOPROTEINASE INHIBITORS | AMGEN INC. | 2002-01-01 | — | — | US | disclosed |
| US-6291450-B1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | AMGEN INC. | 2001-09-18 | — | — | US | disclosed |
| CN-1284947-A | Carboxyl acid substituted heterocycles as metalloproteinase inhibitors | AMGEN INC (US) | 2001-02-21 | — | — | CN | disclosed |
| EP-1042297-A1 | CARBOXYL ACID SUBSTITUTED HETEROCYCLES AS METALLOPROTEINASE INHIBITORS | Amgen Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1040099-A1 | AZEPINE OR LARGER MEDIUM RING DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Amgen Inc., (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6107291-A | ANTIINFLAMMATORY AGENT | AMGEN INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1999032451-A1 | AZEPINE OR LARGER MEDIUM RING DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AMGEN INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032452-A1 | CARBOXYL ACID SUBSTITUTED HETEROCYCLES AS METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | SLC15A1 2561/4885LTA4H 3978/4885ALDH1A1 1312/4885 |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | SLC15A1 1791/4885LTA4H 3498/4885ALDH1A1 296/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | SLC15A1 2243/4885LTA4H 3924/4885ALDH1A1 433/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | SLC15A1 1207/4885LTA4H 2842/4885ALDH1A1 1025/4885 |
| US-20020065269-A1 | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use | HCAR2, HCAR1, TNF | SLC15A1 1347/4885LTA4H 128/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.